China SXT Operating Income Over Time
| SXTC Stock | USD 0.03 0.02 38.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out China SXT Performance and China SXT Correlation. Will Personal Care Products sector continue expanding? Could China diversify its offerings? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every China SXT data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.426 | Earnings Share (0.23) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets |
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, China SXT's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare China SXT Pharmaceuticals and related stocks such as Atlantic International, Incannex Healthcare, and Cybin Inc Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATLN | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.5 M) | (2.4 M) | (2.3 M) | (949.7 K) | (35.7 M) | 6 M | (3.5 M) | (21.8 M) | (19.7 M) | (18.7 M) |
| IXHL | (147 K) | (3.4 M) | (10 M) | (6.3 M) | (1.9 M) | (577.2 K) | (16.1 M) | (2.4 M) | (2 M) | (2.8 M) | (8.2 M) | (10.2 M) | (13.6 M) | (45 M) | (23.8 M) | (21.4 M) | (20.3 M) |
| AVR | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (16.9 M) | (31.1 M) | (48.1 M) | (78.4 M) | (70.5 M) | (67 M) |
| SAVA | (4.7 M) | (3.5 M) | (3.9 M) | 31.4 M | (12.4 M) | (14.2 M) | (15 M) | (11.9 M) | (6.7 M) | (5 M) | (6.4 M) | (32.9 M) | (80 M) | (106 M) | (141.4 M) | (127.3 M) | (120.9 M) |
| FATE | (13.3 M) | (13.3 M) | (13.6 M) | (17.7 M) | (24.9 M) | (27.8 M) | (32 M) | (42.1 M) | (67.1 M) | (100.7 M) | (128.1 M) | (217 M) | (308.4 M) | (190.5 M) | (210.3 M) | (189.2 M) | (179.8 M) |
| IPHA | (6.4 M) | (7.6 M) | (3.4 M) | (2.8 M) | (20 M) | (10.8 M) | 7.6 M | (40 M) | 5.1 M | (27.1 M) | 1.1 M | (47.8 M) | (57.4 M) | (12.7 M) | (51.6 M) | (46.4 M) | (44.1 M) |
| MIST | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (23.8 M) | (57.9 M) | (50.7 M) | (43.1 M) | (59.6 M) | (61.1 M) | (42.1 M) | (37.9 M) | (39.8 M) |
| NVCT | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (12.9 M) | (19.2 M) | (22.9 M) | (19.8 M) | (17.9 M) | (18.8 M) |
China SXT Pharmaceuticals and related stocks such as Atlantic International, Incannex Healthcare, and Cybin Inc Operating Income description
Operating Income is the amount of profit realized from China SXT Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of China SXT Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| China SXT Pharmaceuticals | SXTC |
Specialization | Consumer Staples, Drug Manufacturers - Specialty & Generic |
| Business Address | 178 Taidong Road |
| Exchange | NASDAQ Exchange |
USD 0.031
Check out China SXT Performance and China SXT Correlation. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
China SXT technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.